Status:
COMPLETED
Improving White Matter Integrity With Thyroid Hormone
Lead Sponsor:
University of Illinois at Chicago
Collaborating Sponsors:
National Institute of Neurological Disorders and Stroke (NINDS)
Conditions:
Hypothyroidism
Eligibility:
All Genders
21-60 years
Brief Summary
Animal studies have shown that thyroid hormone can improve white matter integrity after damage to myelin, which insulates and protects nerves. It is currently unknown whether this type of repair can o...
Detailed Description
The ability to promote and support remyelination has wide-ranging implications for a number of neuropsychiatric conditions from multiple sclerosis to major depression. Pre-clinical evidence has demons...
Eligibility Criteria
Inclusion
- Age: 21-60 years of age
- A diagnosis of primary hypothyroidism from autoimmune thyroiditis (Hashimoto)
- Able to give informed consent.
Exclusion
- Major depressive disorder with or without active suicidal ideation
- Mild or major neurocognitive disorder;
- Presence of contraindications to magnetic resonance imaging (presence of ferrous-containing metals within the body (e.g., aneurysm clips, shrapnel/retained particles)
- Inability to tolerate small, enclosed spaces without anxiety (e.g., claustrophobia)
- Unwilling/unable to sign informed consent document
- Positive urine drug screen results;
- Pregnancy (positive pregnancy test), trying to become pregnant, or lactation
Key Trial Info
Start Date :
November 8 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 8 2019
Estimated Enrollment :
5 Patients enrolled
Trial Details
Trial ID
NCT04098991
Start Date
November 8 2017
End Date
November 8 2019
Last Update
April 10 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Illinois at Chicago
Chicago, Illinois, United States, 60612